220 related articles for article (PubMed ID: 32138766)
21. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
[TBL] [Abstract][Full Text] [Related]
22. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
23. [The Role of Plasma CDO1 Methylation in the Early Diagnosis of Lung Cancer].
Wang P; Zhao H; Shi R; Liu X; Liu J; Ren F; Zhao Q; Zhang H; Li Y; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):314-320. PubMed ID: 32317090
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
25. A panel of promoter methylation markers for invasive and noninvasive early detection of NSCLC using a quantum dots-based FRET approach.
Ma Y; Bai Y; Mao H; Hong Q; Yang D; Zhang H; Liu F; Wu Z; Jin Q; Zhou H; Cao J; Zhao J; Zhong X; Mao H
Biosens Bioelectron; 2016 Nov; 85():641-648. PubMed ID: 27240011
[TBL] [Abstract][Full Text] [Related]
26. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients.
An Q; Liu Y; Gao Y; Huang J; Fong X; Li L; Zhang D; Cheng S
Cancer Lett; 2002 Dec; 188(1-2):109-14. PubMed ID: 12406555
[TBL] [Abstract][Full Text] [Related]
27. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
28. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.
Ulivi P; Foschi G; Mengozzi M; Scarpi E; Silvestrini R; Amadori D; Zoli W
Int J Mol Sci; 2013 May; 14(5):10332-42. PubMed ID: 23681013
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation analysis of selected genes for the detection of early-stage lung cancer using circulating cell-free DNA.
Yang Z; Qi W; Sun L; Zhou H; Zhou B; Hu Y
Adv Clin Exp Med; 2019 Mar; 28(3):355-360. PubMed ID: 30516882
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
31. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
[TBL] [Abstract][Full Text] [Related]
32. Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
Suga Y; Miyajima K; Oikawa T; Maeda J; Usuda J; Kajiwara N; Ohira T; Uchida O; Tsuboi M; Hirano T; Kato H; Ikeda N
Oncol Rep; 2008 Nov; 20(5):1137-42. PubMed ID: 18949413
[TBL] [Abstract][Full Text] [Related]
33. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
34. Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer.
Li L; Shen Y; Wang M; Tang D; Luo Y; Jiao W; Wang Z; Yang R; Tian K
Clin Transl Oncol; 2014 Jun; 16(6):581-9. PubMed ID: 24154929
[TBL] [Abstract][Full Text] [Related]
35. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
36. Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer.
Zhong Y; Ding X; Bian Y; Wang J; Zhou W; Wang X; Li P; Shen Y; Wang JJ; Li J; Zhang C; Wang C
Mol Oncol; 2021 Sep; 15(9):2439-2452. PubMed ID: 33340250
[TBL] [Abstract][Full Text] [Related]
37. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
39. CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.
Du Q; Li E; Liu Y; Xie W; Huang C; Song J; Zhang W; Zheng Y; Wang H; Wang Q
Cancer Med; 2018 Feb; 7(2):325-335. PubMed ID: 29356357
[TBL] [Abstract][Full Text] [Related]
40. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
